CDMO Kincell inks CAR-T supply pact with Imugene, pays $6M for its North Carolina manufacturing site and staff

16 Apr 2024
·
Deals
www.fiercepharma.com
Cell TherapyImmunotherapy
CDMO Kincell inks CAR-T supply pact with Imugene, pays $6M for its North Carolina manufacturing site and staff
Preview
Source: FiercePharma
Under the deal, Kincell Bio will pay Imugene $6 million in cash and milestone payments over a three-year span.
CDMO Kincell Bio and immuno-oncology biotech Imugene are making some exchanges under a new strategic partnership.
For $6 million over three years of upfront and milestone-driven payments, Kincell will take on Imugene’s North Carolina cell manufacturing site and the associated staffers.
The duo further struck a supply pact, making Kincell responsible for manufacturing Imugene’s CAR-T candidate azer-cel for ongoing clinical trials, the companies said in a press release.
While Kincell gets a new 32,800-square-foot site in Research Triangle Park (RTP), Imugene will be able to save $32 million through staff cost cuts, manufacturing efficiencies and overhead savings over the next three years.
The asset sale and staffer transfer—plus the azer-cel outsourcing arrangement—will slash Imugene’s total head count by 50% and extend its cash runway through 2026, the biotech said.
“This partnership allows us to focus on our key capabilities, namely the development of novel cancer treatments,” Imugene’s CEO Leslie Chong said in a statement. “With the transaction, we look forward to continuing to work with many of our former manufacturing colleagues in a new relationship as our contract development and manufacturing organization partner.”
The company describes azer-cel as a “potential first in class” allogeneic CAR-T candidate for diffuse large B-cell lymphoma patients who have relapsed following CAR-T therapy.
As for Kincell, the buy “accelerates our ability to expand our service offerings for cell therapy developers,” CEO Bruce Thompson added.
The RTP site was designed with the flexibility to allow for future expansions. Kincell plans to “evolve” the plant’s capabilities to manufacture a range of autologous and allogenic products, it said.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.